About the Company
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $GNCA News
Genocea Biosciences Inc GNCAQ
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Genocea Biosciences Inc Ordinary Shares (GNCA)
Nasdaq provides company’s SEC filings, which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC ...
Astellas, Poseida Collaborate To Develop Novel Allogeneic Cell Therapies In Oncology
Astellas Pharma Inc. (ALPMY, ALPMY) said that its subsidiary, Xyphos Biosciences Inc, and Poseida Therapeutics Inc. (PSTX) have ...
Plc Gsk's Net Worth
Plc Gsk has an estimated net worth of $9.11 Billion. This is based on reported shares across multiple companies, which include Wave Life Sciences Ltd., CVRx, Inc., Lyell Immunopharma, Inc ...
PCRX Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in ...
Anixa Biosciences, Inc.
Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. It operates through the following ...
Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase ...
Pulse Biosciences, Inc. (PLSE)
HAYWARD, Calif., April 24, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology ...
IGMS IGM Biosciences, Inc.
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops ...
Precision BioSciences, Inc. (DTIL)
DURHAM, N.C., April 16, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company, today announced the anticipated return of three programs from Prevail Therapeutics Inc ...
Loading the latest forecasts...